Montpellier, April 18th, 2023
Quantum Surgical announces the ongoing clinical trial for the treatment of lung metastases assisted by the Epione® robot. The study is coordinated by Professor Thierry de Baère, Head of the Therapeutic Imaging Department at Gustave Roussy (Villejuif, France), ranked world’s third best cancer hospital in 20231. This study will evaluate the clinical performance and safety of the Epione® device for the treatment of these tumors.
Epione® is a robotic platform capable of assisting interventional radiologists in planning and performing minimally invasive procedures for the percutaneous ablation of tumors in the abdomen. Available in France and the United States, the Epione® robot has already been used in procedures on more than 150 patients with liver or kidney cancer. With this study, Quantum Surgical aims to obtain an extension of its marketing authorizations in Europe and the United States with an indication extended to the treatment of lung tumors.
With more than 2 million new cases worldwide in 2020, including approximately 500,000 in Europe, lung cancer is the leading cause of death for cancer patients (18%)2.
“This study sets a new milestone in the development of Quantum Surgical, and I am proud that it is being done in collaboration with Gustave Roussy, whose teams see the full potential of our technology. This is another step towards the dissemination of our innovation to other cancer patients”. Bertin Nahum, President and co-founder of Quantum Surgical.
- Gustave Roussy dans le TOP 3 mondial des hôpitaux en cancérologie | Gustave Roussy
- Globocan 2020 : https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
About Quantum Surgical
Quantum Surgical is a leading and innovative French medical robotic company in healthcare innovation. It develops intelligent solutions capable of responding to complex and widespread medical challenges. Its Epione® robotic platform for percutaneous ablation is dedicated to the curative and early treatment of cancers. This robotic platform is capable of assisting practitioners in planning, targeting and performing percutaneous ablation procedures on cancerous tumors, particularly those located in the abdomen. Quantum Surgical thus offers a new approach to cancer treatment by enabling standardization of care, and therefore more patients will benefit from innovative, better targeted and less invasive treatments.
Co-founded in 2017 by Bertin Nahum, Quantum Surgical is based in Montpellier, France, and has an international reach.